腹股沟皮下注射法免疫治疗小鼠变应性鼻炎的实验研究  

Experimental study on inguinal subcutaneous immunotherapy for allergic rhinitis in mice

作　　者：赵振安 戴吉[1] 赵婉君[1] 王青云[1] 曹忠胜[1] 

机构地区：[1]苏州大学附属第二医院耳鼻喉科,苏州215004

出　　处：《中国免疫学杂志》2015年第6期785-789,共5页Chinese Journal of Immunology

摘　　要：目的：探讨腹股沟皮下注射法免疫治疗小鼠变应性鼻炎（Allergic rhinitis,AR）的可行性。方法：36只雌性BALB/c小鼠,6~8周龄,随机分为6组,每组6只,包括A空白组、A模型组、A治疗组、B空白组、B模型组和B治疗组（A为腹股沟皮下注射,B为颈背部皮下注射）。卵清蛋白（Ovalbumin,OVA）AR模型建立成功后治疗组用OVA进行免疫治疗,隔天一次,共15次。鼻腔连续激发第7天时,进行小鼠AR症状评分,鼻黏膜变色酸2R染色统计鼻黏膜嗜酸性粒细胞（Eosinophils,EOS）数,ELISA法检测血清OVA-s Ig E表达和鼻腔灌洗液中IL-4和IFN-γ表达,计算IFN-γ与IL-4比值。以SPSS 17.0软件进行数据分析。结果：治疗前,模型组和治疗组AR症状评分均大于5,治疗后,A治疗组AR症状评分小于5。A空白组、A模型组、A治疗组、B空白组、B模型组和B治疗组EOS数分别为0.78±0.31、21.60±2.90、10.43±2.56、0.83±0.46、22.44±3.39和23.40±4.24,A治疗组EOS数较A模型组明显减少,差异具有显著性（P〈0.05）,B治疗组EOS数与B模型组比较,差异无显著性（P〉0.05）;空白组OVA-s Ig E的表达为阴性,其余组为阳性;各组IFN-γ与IL-4比值分别为10.75±3.38、10.38±3.08、3.02±0.69、2.71±0.89、2.52±0.30和5.45±1.41,A治疗组IFN-γ与IL-4比值较A模型组明显升高,差异具有显著性意义（P〈0.05）,B治疗组IFN-γ与IL-4比值与B模型组比较,差异无显著性（P〉0.05）。结论：腹股沟皮下注射免疫治疗小鼠变应性鼻炎效果好,周期短,操作简单,可行性好,是特异性免疫治疗小鼠变应性鼻炎的一种新方法。Objective： To explore the feasibility of inguinal subcutaneous immunotherapy for allergic rhinitis（ AR） in mice. Methods： 36 female BALB / c mice were divided randomly into six groups（ n = 6 per group） including the control A,the model A,the treatment A groups,and the control B,the model B,the treatment B groups（ inguinal subcutaneous immunotherapy for group A,cervical back subcutaneous immunotherapy for for group B）. AR model was established with ovalbumin. At 25 to 55 days,ovalbumin immunotherapy were performed in treatment groups,once two days,15 times totally. After intranasal rechallenge was performed at 56 to 62 days the AR symptom scores were documented. The eosinophils（ EOS） in the nasal mucosa were measured by chromotropic acid 2R staining. Ovalbumin-specific Ig E（ OVA-s Ig E） in the serum and expression of interferon-γ and interleukin-4 in the nasal lavage were measured by enzyme-linked immunosorbent assay meanwhile the ratio of interferon-γ and interleukin-4 was calc μlated. SPSS17. 0 software was used to analyze the data. Results： Before treatment,the AR symptom scores of the model and treatment groups were more than5. After treatment,the treatment A group were less than 5. The EOS count of the control A,model A,treatment A groups and the control B,model B,treatment B groups was 0. 78 ± 0. 31,21. 60 ± 2. 90,10. 43 ± 2. 56,0. 83 ± 0. 46,22. 44 ± 3. 39,23. 40 ± 4. 24,respectively. The EOS count of the treatment A group was significantly lower than those in model A group（ P〈0. 05）. There was no significant difference between treatment B and model B group（ P〉0. 05）. OVA-s Ig E expressed was negative in control groups and positive in other groups. The ratio of interferon-γ and interleukin-4 was 10. 75 ± 3. 38,10. 38 ± 3. 08,3. 02 ± 0. 69,2. 71 ± 0. 89,2. 52 ± 0. 30,5. 45 ±1. 41,respectively. The ratio in treatment A group was significantly higher than those in model A group（ P〈0. 05）. There was no significant difference between treatment B and mod

关 键 词：变应性鼻炎 卵清蛋白 免疫治疗 皮下注射 免疫球蛋白E 白细胞介素4 干扰素Γ 

分 类 号：R765.22[医药卫生—耳鼻咽喉科]